MBIO - Mustang Bio, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
3.6500
-0.0500 (-1.35%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close3.7000
Open3.7900
Bid0.0000 x 800
Ask0.0000 x 1300
Day's Range3.3000 - 3.8398
52 Week Range1.7800 - 4.8500
Volume923,817
Avg. Volume317,220
Market Cap156.889M
Beta (5Y Monthly)1.53
PE Ratio (TTM)N/A
EPS (TTM)-1.2290
Earnings DateMay 11, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Trade Alert: The President Of Mustang Bio, Inc. (NASDAQ:MBIO), Manuel Litchman, Has Just Spent US$533k Buying 545% More Shares
    Simply Wall St.

    Trade Alert: The President Of Mustang Bio, Inc. (NASDAQ:MBIO), Manuel Litchman, Has Just Spent US$533k Buying 545% More Shares

    Mustang Bio, Inc. (NASDAQ:MBIO) shareholders (or potential shareholders) will be happy to see that the President...

  • Is Mustang (MBIO) Stock a Solid Choice Right Now?
    Zacks

    Is Mustang (MBIO) Stock a Solid Choice Right Now?

    Mustang (MBIO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

  • GlobeNewswire

    Mustang Bio Announces Presentations at 23rd Annual Meeting of the American Society of Gene & Cell Therapy

    WORCESTER, Mass., May 12, 2020 -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs.

  • GlobeNewswire

    Mustang Bio Reports First Quarter 2020 Financial Results and Recent Corporate Highlights

    WORCESTER, Mass., May 11, 2020 -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs.

  • GlobeNewswire

    Mustang Bio Receives Advanced Therapy Medicinal Product Classification from European Medicines Agency for MB-107 Lentiviral Gene Therapy for X-Linked Severe Combined Immunodeficiency

    Mustang Bio, Inc. (“Mustang”) (MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that the European Medicines Agency (“EMA”) has granted Advanced Therapy Medicinal Product (“ATMP”) classification to MB-107, Mustang’s lentiviral gene therapy for the treatment of X-linked severe combined immunodeficiency (“XSCID”), also known as bubble boy disease. The U.S. Food and Drug Administration (“FDA”) previously granted Regenerative Medicine Advanced Therapy (“RMAT”) designation to MB-107 for the treatment of XSCID in August 2019.

  • Before You Buy Mustang Bio, Inc. (NASDAQ:MBIO), Consider Its Volatility
    Simply Wall St.

    Before You Buy Mustang Bio, Inc. (NASDAQ:MBIO), Consider Its Volatility

    If you own shares in Mustang Bio, Inc. (NASDAQ:MBIO) then it's worth thinking about how it contributes to the...

  • GlobeNewswire

    Mustang Bio Reports Full-Year 2019 Financial Results and Recent Corporate Highlights

    NEW YORK, March 16, 2020 -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in.

  • 3 Stocks That Should Bounce Back Once Coronavirus Fears Fade
    TipRanks

    3 Stocks That Should Bounce Back Once Coronavirus Fears Fade

    Is now the right time to invest in stocks? It’s possible that even the most guru-like among Wall Street observers will find the question hard to answer. The markets have yo-yoed dramatically over the last couple of weeks. After posting losses not seen since the 2008 financial meltdown, the S&P 500 closed last week with the best one-day point gain since 2008. As the British investor John Templeton once said, “the time of maximum pessimism is the best time to buy and the time of maximum optimism is the best time to sell.” The coronavirus outbreak has affected the investment market worldwide, resulting in a number of enticing entry points, according to some analysts. With this in mind, using TipRanks’ Stock Screener tool, we were able to get the scoop on 3 stocks reeling from the virus’ impact, but poised for a strong turnaround once the coronavirus outbreak settles. Live Nation Entertainment (LYV) The show must go on, they say. Or possibly paused to restart at a later date, as things currently stand. Amongst the companies taking a hit from the impact of COVID-19, are those who rely on the gatherings of vast crowds. Sports events are likely to feel the pinch in the near-term, along with Live Nation’s bread and butter, live gigs and events. Shares of the live entertainment company have been hit hard, falling more than 41% over the last month. Recent cancellation announcements made by the South By Southwest festival in Austin, Texas and the Ultra Music Festival in Miami, Florida are likely to be followed by others in the days ahead. Things would probably be panning out quite differently for Live Nation had business commenced as usual. The recent coronavirus driven pullback comes off the back of a strong Q4 report. Live Nation reported fourth quarter revenue of $2.89 billion, an 11% year-over-year increase. The figure also lands above the $2.80 billion consensus estimate. A solid showing in the Concerts segment, which posted revenue of $2.30 billion, beating the Street’s call for $2.20 billion and displaying a year-over-year gain of 12%, is to thank for the result. Looking ahead, the company said it has already sold 38 million tickets for shows in 2020, indicating a 10% increase from the same period last year. Confirmed arena, stadiums and amphitheater shows are up 30% year-over-year. Cowen’s Stephen Glagola argues “fear of coronavirus is a buying opportunity.” The analyst believes the current valuation is “very attractive with shares now trading at~14x our 2021 EV/EBITDA.” The analyst added, “The bulk of Live Nation's 2020 concert season (~70% of expected attendance) runs from June through December. In the scenario COVID-19 virus continues to propagate in the U.S. and Europe, management noted they have the flexibility of re-routing/ rescheduling tours, and artists are largely paid when the show occurs helping to limit costs. 70% of FY20 budgeted high-margin sponsorship revenue is committed under multi-year contracts dispersed across the company's diversified concerts portfolio (now in all genres, geographies, and venue types).” Glagola, therefore, reiterated an Outperform on LYV, along with an $85 price target. Should the target be met, investors will be pocketing a 98% gain in the next 12 months. The Street is with the Cowen analyst. 3 additional Buy ratings add up to a Strong Buy consensus rating. At $81.67, the average price target presents possible upside of 91%. (See Live Nation price targets and analyst ratings on TipRanks) Planet Fitness (PLNT) We move on to an entirely different industry, but one presented with a similar problem right now. This affordable gym chain with an ‘everyone is welcome’ motto has been posting losses in the market. So far, PLNT stock is down by 28% in 2020. Planet Fitness monthly plans can cost only $10 a month, the affordability playing a major factor in its growth story. The cheap price tag could also play a part in people’s willingness to hold onto their memberships until the fear of catching the virus subsides. On the other hand, coronavirus-related fears are likely to result in fewer new memberships, which could lead to a significant deceleration in Planet Fitness' growth in the quarters ahead. PLNT posted solid beats in its latest quarterly statement; EPS of $0.44 beat the estimate by $0.03. At $191.51 million, revenue grew year-over-year by 9.8%, and beat the Street’s forecast by $1.93 million. The crucial franchise segment grew 30%, which was much stronger-than-anticipated—with same-store sales rising 8.6%. The results, though, yielded a frosty reception, as investors were disappointed when 2020 guidance landed below the estimates; in the coming year, management expects revenue to increase by only 12%, below the 20% growth achieved in 2019. Guggenheim’s John Heinbockel believes the conservative guidance is consistent with the company’s history and tells investors to “buy on weakness.” Heinbockel said, “The unique PLNT secular growth story is intact, with 4Q EBITDA rising a stronger-than-we-expected 23% and a conservative initial 2020 guide laying the groundwork for another ‘beat and raise’ year. Value-oriented membership share gains, moderate pricing power, and scale-related margin expansion are driving well above average, highly visible and capital-light sales/EBITDA growth. This growth not only merits the current premium valuation, but likely deserves modest expansion.” As a result, the 4-star analyst maintained a Buy rating on PLNT and believes a share price of $85 will be attained over the next 12 months, indicating potential upside of 57%. (To watch Heinbockel’s track record, click here) Looking at the consensus breakdown, 6 Buys in addition to 3 Holds coalesce into a Moderate Buy consensus rating for PLNT. The analysts forecast 63% upside, should the average price target of $87.88 be met over the coming months. (See PLNT stock-price forecast on TipRanks)Mustang Bio Inc (MBIO)  Last on our list is Mustang Bio. Interestingly, out of the three names on the list, Mustang has been hit the hardest. Year-to-date, MBIO’s share price is down by 50%. Cantor Fitzgerald’s Kristen Kluska believes a turnaround is in the cards for MBIO as she sees “no fundamental reason outside of overall stock pressure related to COVID-19,” for the pullback. Mustang develops next generation cell and gene therapies that could potentially serve as cures for hematologic cancers and rare genetic diseases. The company’s pipeline has a number of drugs in various stages of development, but one is currently leading the way. The company is developing a gene therapy for XSCID (X-linked severe combined immunodeficiency), commonly known as "bubble boy" disease, a rare genetic condition that results in a severely impaired immune system. Patients with XSCID are often forced to live in sterile environments as they are very susceptible to infections. The disease could finally have a treatment or even a cure, should Mustang’s initial promising data results hold up in ongoing and future trials. Kluska said, “XSCID is an indication that has been studied for many years, and the severity is well understood, which has led to newborn screening implementation in all 50 states. All patients from the St. Jude trial, presented at ASH 2019 remain alive, up to the age of 39.9 months. We believe this echoes the FDA comments that a drug may be clearly showing effect if survivability trends are observed in even just a few patients… We believe a current market cap of ~$130 million does not reflect the potential of Mustang's pipeline that includes ex-vivo gene therapies and CAR-T therapies of ~ten indications.” Bearing this in mind, Kluska reiterated her Overweight rating on MBIO along with a $7 price target. This conveys the analyst’s confidence in Mustang’s ability to soar 241% in the next year. (To watch Kluska’s track record, click here) Currently, there are only two other analysts with a view on the rare disease fighter’s prospects. Both, though, rate the biotech a Buy, therefore, bestowing Strong Buy status on Mustang. The average price target is even higher than Kluska’s, and at $10, implies potential upside of an impressive 388%. (See Mustang Bio stock analysis on TipRanks)

  • GlobeNewswire

    Mustang Bio Announces First Subject Treated in Phase 1/2 Trial with the Optimized CD20-targeted CAR T Cell Therapy MB-106

    Mustang Bio, Inc. (“Mustang”) (MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that the first subject treated with the optimized MB-106 (CD20-targeted, autologous CAR T cell therapy) manufacturing process, developed in collaboration between Mustang and Fred Hutchinson Cancer Research Center (“Fred Hutch”), has achieved a complete response (CR) at the lowest starting dose in an ongoing Phase 1/2 clinical trial. The trial is evaluating the safety and efficacy of MB-106 in subjects with relapsed or refractory B-cell non-Hodgkin lymphomas.

  • GlobeNewswire

    Mustang Bio to Present at the Phacilitate Leaders World & World Stem Cell Summit 2020

    NEW YORK, Jan. 22, 2020 -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell.

  • Mustang Bio, Inc. (MBIO) Upgraded to Buy: What Does It Mean for the Stock?
    Zacks

    Mustang Bio, Inc. (MBIO) Upgraded to Buy: What Does It Mean for the Stock?

    Mustang Bio, Inc. (MBIO) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  • Hedge Funds Are Done Buying Mustang Bio, Inc. (MBIO)
    Insider Monkey

    Hedge Funds Are Done Buying Mustang Bio, Inc. (MBIO)

    A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshly-submitted public filings disclose money managers’ equity positions as of the end of the three-month period […]

  • GlobeNewswire

    Mustang Bio Announces Updated Clinical Data on MB-107 Lentiviral Gene Therapy for Patients with X-Linked Severe Combined Immunodeficiency

    MB-107 preceded by low-dose busulfan conditioning continues to be well tolerated and results in development of functional immune system in newly diagnosed infants with XSCID.

  • GlobeNewswire

    Mustang Bio to Participate in the Evercore ISI 2nd Annual HealthCONx Conference

    NEW YORK, Dec. 02, 2019 -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell.

  • GlobeNewswire

    Mustang Bio Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights

    NEW YORK, Nov. 12, 2019 -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell.

  • GlobeNewswire

    Mustang Bio Announces MB-107 Lentiviral Gene Therapy and MB-106 CD20-Targeted CAR T Data Selected for Presentations at 61st American Society of Hematology Annual Meeting

    St. Jude Children’s Research Hospital and the National Institutes of Health to present updated MB-107 clinical data for the treatment of X-linked severe combined.

  • GlobeNewswire

    Mustang Bio Announces Dosing of First Participant in Phase 1 Clinical Trial of MB-108 (Oncolytic Virus C134) to Treat Glioblastoma

    Mustang Bio, Inc. (“Mustang”) (MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, announced today that the first participant has been dosed in a Phase 1 clinical trial to determine the safety and efficacy of MB-108 (oncolytic virus C134), an attenuated herpes simplex virus type 1, in recurrent glioblastoma multiforme.

  • GlobeNewswire

    Mustang Bio Announces City of Hope Receives $4.1 Million in Grant Awards for Recently Opened First-of-Its-Kind Clinical Trial for Patients with Recurrent Malignant Glioma

    NEW YORK, Oct. 10, 2019 -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell.

  • Have Insiders Been Buying Mustang Bio, Inc. (NASDAQ:MBIO) Shares This Year?
    Simply Wall St.

    Have Insiders Been Buying Mustang Bio, Inc. (NASDAQ:MBIO) Shares This Year?

    It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...

  • GlobeNewswire

    Mustang Bio to Participate in October 2019 Investor Conferences

    NEW YORK, Sept. 26, 2019 -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in.

  • GlobeNewswire

    Mustang Bio Announces Phase 1 Clinical Trial Evaluating MB-105 for Prostate Stem Cell Antigen-Positive Castration-Resistant Prostate Cancer Enrolling Patients at City of Hope

    Mustang Bio, Inc. (“Mustang”) (MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that City of Hope, a world-renowned independent cancer research and treatment center, has opened and is beginning to treat its first patients in a Phase 1 clinical trial of MB-105, a prostate stem cell antigen (PSCA) chimeric antigen receptor (CAR) T technology, for the treatment of prostate cancer. MB-105 was developed in the laboratory of Saul Priceman, Ph.D., assistant professor in City of Hope’s Department of Hematology & Hematopoietic Cell Transplantation and a scientist in the T Cell Therapeutics Research Laboratory led by Stephen Forman, M.D., leader of City of Hope’s Hematologic Malignancies and Stem Cell Transplantation Institute and the Francis & Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation.

  • GlobeNewswire

    Mustang Bio to Present at Scientific Conferences in September 2019

    NEW YORK, Sept. 09, 2019 -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in.

  • Mustang Bio Adopts CryoStor® Freeze Media and evo® Cold Chain System for Cell and Gene Therapy Manufacturing and Distribution
    PR Newswire

    Mustang Bio Adopts CryoStor® Freeze Media and evo® Cold Chain System for Cell and Gene Therapy Manufacturing and Distribution

    Pipeline and Clinical Trials Focused on Cancers and Genetic Disorders BOTHELL, Wash. , Sept. 3, 2019 /PRNewswire/ --   BioLife Solutions , Inc. (NASDAQ: BLFS), a leading developer and supplier of a portfolio ...

  • GlobeNewswire

    Mustang Bio to Present at September 2019 Investor Conferences

    NEW YORK, Aug. 29, 2019 -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell.

  • GlobeNewswire

    Mustang Bio Announces License Agreement with CSL Behring for the Cytegrity™ Stable Producer Cell Line for the Production of MB-107 Lentiviral Gene Therapy

    Mustang Bio, Inc. (“Mustang”) (MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that it has entered into a license agreement with CSL Behring for the Cytegrity™ stable producer cell line developed and used by St. Jude Children’s Research Hospital (“St. Jude”). Cytegrity™ stable producer cell line will be used to produce the viral vector for Mustang Bio’s MB-107 lentiviral gene therapy program for the treatment of X-linked severe combined immunodeficiency (XSCID).